Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Epstein–Barr virus can inhibit genotoxin-induced G1 arrest downstream of p53 by preventing the inactivation of CDK2

Oncogene volume 22, pages 7181–7191 (2003)Cite this article

An Erratum to this article was published on 19 August 2004

Abstract

Epstein–Barr virus (EBV) is involved in the pathogenesis of several B cell lymphoproliferations, but the precise contribution it makes to the aetiology of each remains unclear. In vitro, the virus has potent growth transforming activity and efficiently induces the continuous proliferation of normal human B cells. A comparison of EBV-infected primary B cells with an isogenic population induced to proliferate by CD40-ligand (CD40L) and IL4 has revealed that EBV can override – by a novel mechanism – the p53/pRb-mediated G1 checkpoint activated in normal B cells by a genotoxic stress. In cells responding to cisplatin, although p53 is stabilized and activated, EBV latent gene expression appears to inhibit the accumulation of newly synthesized p21WAF1/CIP1 and the downregulation of cyclin D2 that occur in the normal cells. Consequently, in the EBV-infected cells, CDK2 remains active, hyperphosphorylation of pRb is maintained and the replication of damaged DNA can occur. Under conditions of severe genomic stress, this absence of p21WAF1/CIP1 function can result in apoptosis; however, when damage is less sustained, genomic instability may arise and this in turn could contribute to the development of a variety of EBV-associated B cell malignancies.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 8
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Agami R and Bernards R . (2002). Cancer Lett., 177, 111–118.

  • Allday MJ, Sinclair A, Parker G, Crawford DH and Farrell PJ . (1995a). EMBO J., 14, 1382–1391.

  • Allday MJ, Inman GJ, Crawford DH and Farrell PJ . (1995b). EMBO J., 14, 4994–5005.

  • Banchereau J, dePaoli P, Valle A, Garcia E and Rousset F . (1991). Science, 251, 70–72.

  • Bartek J and Lukas J . (2001). Curr. Opin. Biol., 13, 738–747.

  • Blagosklonny MV, Wu GS, Omura S and El-Deiry WS . (1996). Biochem. Biophys. Res. Commun., 227, 564–569.

  • Bornkamm GW and Hammerschmidt W . (2001). Philos. Trans. R. Soc. Lond. B, 356, 437–459.

  • Cannell EJ, Farrell PJ and Sinclair AJ . (1996). Oncogene, 13, 1413–1421.

  • Cannell EJ, Farrell PJ and Sinclair AJ . (1998). FEBS Lett., 439, 297–301.

  • Chattopadhyay D, Ghosh MK, Mal A and Harter ML . (2001). J. Virol., 75, 9844–9856.

  • Dotto GP . (2000). Biochim. Biophys. Acta, 1471, M43–M56.

  • Garrone P, Neidhardt EM, Garcia E, Galibert L, van Kooten C and Banchereau J . (1995). J. Exp. Med., 182, 1265–1273.

  • Hartwell LH and Kastan MB . (1994). Science, 266, 1821–1828.

  • Hoeijmakers JHJ . (2001). Nature, 411, 366–374.

  • Kelly G, Bell A and Rickinson AB . (2002). Nat. Med., 8, 1098–1104.

  • Knowles DM, Cesarman E, Chadburn A, Frizzera G, Chen J, Rose EA and Michler RE . (1995). Blood, 85, 552–565.

  • Kriwacki RW, Hengst L, Tennant L, Reed SI and Wright PE . (1996). Proc. Natl. Acad. Sci. USA, 93, 11504–11509.

  • Linndstrom MS and Wiman KG . (2002). Cancer Biol., 12, 381–387.

  • Lui C-W, Corboy MJ, DeMartino GN and Thomas PJ . (2003). Science, 299, 408–411.

  • Maki CG and Howley PM . (1997). Mol. Cell. Biol., 17, 355–363.

  • Palmero I, Holder A, Sinclair A, Dickson C and Peters G . (1993). Oncogene, 8, 1049–1054.

  • Parker GA, Touitou R and Allday MJ . (2000). Oncogene, 19, 700–709.

  • Paulovich AG, Toczyski DP and Hartwell LH . (1997). Cell, 88, 315–321.

  • Polyak K, Waldmann T, He TC, Kinzler KW and Vogelstein B . (1996). Genes Dev., 10, 1945–1952.

  • Rickinson AB . (2001). Philos. Trans. R. Soc. Lond. B, 356, 595–604.

  • Rousset F, Peyrol S, Garcia E, Vezzio N, Andujar M, Grimaud JA and Banchereau J . (1995). Int. Immunol., 7, 1243–1253.

  • Scott MT, Ingram A and Ball KL . (2002). EMBO J., 21, 6771–6780.

  • Sheaff RJ, Singer JD, Swanger J, Smitherman M, Roberts JM and Clurman B . (2000). Mol. Cell, 5, 403–410.

  • Sherr CJ and Roberts JM . (1999). Genes Dev., 13, 1501–1512.

  • Shvarts A, Brummelkamp TR, Scheeren F, Koh E, Daley GC, Spits H and Bernards R . (2002). Genes Dev., 16, 681–686.

  • Sinclair AJ, Palmero I, Peters G and Farrell PJ . (1994). EMBO J., 13, 3321–3328.

  • Speck S . (2002). Nat. Med., 8, 1086–1087.

  • Spender LC, Cannell EJ, Hollyoake M, Wensing B, Gawn JM, Brimmell M, Packham G and Farrell PJ . (1999). J. Virol., 73, 4678–4688.

  • Spender LC, Cornish GH, Rowland B, Kempkes B and Farrell PJ . (2001). J. Virol., 75, 3537–3546.

  • Spruck CH, Won K-A and Reed S . (1999). Nature, 401, 297–300.

  • Thorley-Lawson D . (2001). Nat. Rev. Immunol., 1, 75–82.

  • Thorley-Lawson D and Babcock GJ . (1999. Life Sci., 65, 1433–1453.

  • Timms JM, Bell A, Flavell JR, Murray PG, Rickinson AB, Traverse-Glehen A, Berger F and Delecluse HJ . (2003). Lancet, 361, 217–223.

  • Touitou R, Richardson J, Bose S, Nakanishi M, Rivett J and Allday MJ . (2001). EMBO J., 20, 2367–2375.

  • Wade M and Allday MJ . (2000). Mol. Cell. Biol., 20, 1344–1360.

  • Waldman T, Lengauer C, Kinzler KW and Vogelstein B . (1996). Nature, 381, 713–716.

  • Zhang Y, Fujita N and Tsuruo T . (1999). Oncogene, 18, 1131–1138.

Download references

Acknowledgements

We are grateful to Paul Farrell, Roger Watson and Mark Wade for helpful comments on the manuscript and to Xin Lu and Martin Rowe for antibodies. We also like to thank the Wellcome Trust for financial support through programme Grant No. 056822 to MJA and a Wellcome Trust Prize Studentship to JO.

Author information

Authors and Affiliations

  1. Department of Virology and Ludwig Institute for Cancer Research, Wright-Fleming Institute, Faculty of Medicine, Imperial College London, Norfolk Place, London, W2 1PG, UK

    Jenny O'Nions & Martin J Allday

Authors
  1. Jenny O'Nions
    View author publications

    Search author on:PubMed Google Scholar

  2. Martin J Allday
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Martin J Allday.

Rights and permissions

Reprints and permissions

About this article

Cite this article

O'Nions, J., Allday, M. Epstein–Barr virus can inhibit genotoxin-induced G1 arrest downstream of p53 by preventing the inactivation of CDK2. Oncogene 22, 7181–7191 (2003). https://doi.org/10.1038/sj.onc.1206838

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/sj.onc.1206838

Keywords

This article is cited by

Search

Advanced search

Quick links